Pemetrexed Maintenance versus Observation in Patients with Advanced Urothelial Carcinoma Who Completed First-Line Platinum-Based Chemotherapy without Disease Progression (PREMIER, KCSG GU16-05)
The PREMIER trial showed that switch maintenance pemetrexed significantly prolonged PFS in aUC patients post-1L platinum-based chemotherapy, with a favorable safety profile. Further studies on combination maintenance therapies are warranted.
Authors
- Jae‐Lyun Lee (ORCID: https://orcid.org/0000-0002-9420-7162)
- Inkeun Park
- Byeong Seok Sohn
- Shinkyo Yoon
- Ilhwan Kim
- Kwonoh Park
- Suee Lee
- Bhumsuk Keam
- Joo-Hwan Park
- Jin Young Kim
- Yoon Ji Choi
Institutions
- Ulsan College (KR)
- Korea University (KR)
- Dong-A University Hospital (KR)
- Asan Medical Center (KR)
- Seoul National University Hospital (KR)
- University of Ulsan (KR)
- Gachon University Gil Medical Center (KR)
- Inje University Haeundae Paik Hospital (KR)
- Inje University Sanggye Paik Hospital (KR)
- Keimyung University Dongsan Medical Center (KR)
- Hanyang University Seoul Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Keimyung University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2024-12-26
- DOI
- https://doi.org/10.4143/crt.2024.1003
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Genentech
- Daiichi Sankyo Europe